. Current predictions estimate that more than 900,000 individuals in the United States will suffer a myocardial infarction (heart attack) or die of CAD this year 3 . As with most complex diseases, an individual's risk of developing CAD is modulated by an interplay between genetic and lifestyle factors 4 . Clinical observations dating back to the 1950s have supported the notion that risk of CAD is heritable 5 . A study of more than 20,000 Swedish twins subsequently confirmed this finding of increased risk for CAD among close relatives, and estimated a heritability of ~50% for fatal CAD 6, 7 . An analysis that quantified heritability using updated genome-wide approaches similarly estimated the heritability of CAD at 40-50% 8 . In the Framingham Heart Study, a family history of cardiovascular disease in a parent or sibling was a strong predictor of incident disease 9, 10 . These seminal studies laid the foundation for the application of emerging human genetics tools to understand the underlying genetic architecture of CAD, to uncover novel biology and to translate these findings into clinical practice.
Substantial progress in our understanding of the genetic underpinnings of CAD has been made since the topic was last reviewed in this journal in 2006 (REF. 11 ). First reported in 2007, genetic association studies have identified ~60 genetic variants with robust links to risk of CAD. Sequencing studies of rare variants have highlighted pathways underlying CAD and, in several cases, directly catalysed the development of novel therapeutic strategies. Large-scale biobanks containing both genetic and clinical information have enabled the assessment of relationships between a given variant and a broad range of human disease states.
In this Review, we outline research efforts to understand the genetic drivers of CAD, the role of human genetics in catalysing CAD drug discovery efforts and the promises and challenges of integrating genetic information into routine clinical practice. cholesterol) in 1938 (REF. 12 ). In 1985, a 5 kb deletion in LDLR, the gene encoding the low-density lipoprotein (LDL) receptor, was identified in a patient with familial hypercholesterol aemia and in his mother. This study was the first to demonstrate that a molecular defect in a single gene can drive CAD risk 13 . Impaired receptor-mediated hepatic uptake of LDL leads to substantially increased levels of circulating cholesterol and premature CAD. Family-based studies similarly identified mutations in APOB (which encodes apolipoprotein B) and gain-offunction mutations in PCSK9 (which encodes proprotein convertase subtilisin/kexin type 9) as additional causes of familial hypercholesterolaemia; mutations in APOB and PCSK9 prevent the binding of LDL particles to LDLRs for uptake and promote LDLR catabolism, respectively 14, 15 . The genetic underpinnings of autosomal recessive hypercholesterolaemia were linked to null mutations in the genes encoding LDLR adaptor protein 1 (LDLRAP1) and ATP-binding cassette sub-family G member 5 (ABCG5) or ABCG8 (REFS 16, 17) .
Beyond familial hypercholesterolaemia and related conditions, the use of family studies to identify monogenic drivers of CAD has proven challenging. A 2003 analysis of a large family implicated a locus at chromosome 15q26 as an autosomal dominant driver of CAD risk. Sequencing of MEF2A, a gene encoding the transcription factor myocyte enhancer factor 2A, which is expressed in the vasculature, identified a 21 bp deletion in each of the affected family members 18 . However, despite biological plausibility, subsequent efforts have failed to confirm an association between loss-of-function variants in MEF2A and CAD 19 , suggesting that this initial report may have been related to a chance finding. Additional linkage analyses of families with early-onset CAD and metabolic risk factors have noted potentially causal missense mutations in the genes encoding LDLRrelated protein 6 (LRP6) and dual specificity tyrosine phosphory lation regulated kinase 1B (DYRK1B) 20, 21 . Owing to the rarity of these geno types, definitive confirmation of these findings in the general population has not yet been possible.
The careful study of families with extreme phenotypes (for example, onset of CAD at a young age in the absence of traditional risk factors) may still prove useful in gene discovery. However, before assuming causality for any given finding, rigorous replication that places the genetic, bioinformatics and experimental results into a broader context is required 22 . Common variant association studies. Despite the tendency to cluster in families, CAD is a complex and common disorder. Genotyping chips designed to capture the majority of common inter-individual genetic variation provided the foundation for common variant association studies (CVAS), also termed genomewide association studies (GWAS). Because common variants occur sufficiently often, it is practical to test each variant individually by comparing its frequency in disease cases and disease-free controls 23 . One operational definition of 'common' is variation with an allele frequency of ≥0.5% (one carrier per 100 individuals) 24 . The first CVAS for CAD were published in 2007, when three independent groups reported common variants at the 9p21 locus that were associated with a ~30% increased risk of CAD per copy of the risk allele [25] [26] [27] . Subsequent studies have both replicated this finding and extended the association to other vascular phenotypes, including carotid atherosclerosis 28 , peripheral arterial disease 29 and stroke 30 . Preliminary evidence suggests that the 9p21 risk variants alter the expression of the non-coding RNA ANRIL, thereby altering the activity of two nearby cyclin-dependent kinase inhibitors (CDKN2A and CDKN2B) that are involved in regulating the cell cycle Coronary artery disease (CAD) refers to the build-up of atherosclerotic plaque in the blood vessels that supply oxygen and nutrients to the heart (reviewed in REF. 126 ). The complex process of atherosclerosis begins early in life and is thought to initiate with dysfunction of endothelial cells that line the coronary arteries; these cells are no longer able to appropriately regulate vascular tone (narrowing or constriction of the vessels) with nitric oxide signalling. Progressive infiltration of the vessel wall by lipoprotein particles carrying cholesterol propagates an inflammatory response by cholesterolloaded macrophage 'foam cells'. Smooth muscle cells underlying the vessel wall proliferate and lead to remodelling of the vessel that can ultimately lead to a narrowing of the vessel that obstructs blood flow. A myocardial infarction (heart attack) is typically caused when a blood clot is incited by a rupture in the surface of the plaque; this process deprives the heart muscle downstream of the blood clot of adequate blood flow and leads to cell death.
Epidemiological studies of CAD demonstrated that age, male gender, smoking, elevated blood pressure, diabetes, obesity and a sedentary lifestyle each lead to an increased risk of suffering from a myocardial infarction (see the figure) . Similarly, increased concentrations of circulating low-density lipoprotein (LDL) cholesterol, increased triglyceride (TG)-rich lipoproteins (a form of fat storage) or decreased high-density lipoprotein (HDL) cholesterol are associated with risk of CAD. In clinical practice, these risk factors can be combined to identify subsets of the population at increased risk of CAD who would most benefit from preventive therapies.
Efforts to prevent CAD (reviewed in REF. 127 ) begin with encouraging adherence to a healthy lifestyle -for example, not smoking, avoiding obesity, a healthy diet and regular exercise -in the population. Higher-risk individuals benefit from additional medications to reduce LDL cholesterol (for example, statins), lower blood pressure or help prevent formation of a blood clot (for example, aspirin). Should an individual ultimately suffer a myocardial infarction, blood flow can be restored via a procedure to place a stent in the narrowed vessel or bypass it via open-heart surgery. Because of a substantial risk of recurrence, medical therapy is intensified in these individuals. Nature Reviews | Genetics 
Allele frequency
The relative frequency of an allele (specific genetic variant) in the population; typically reported as the proportion of all chromosomes in the population that carry an allele.
Inactivating mutations
Variants that disrupt the ability of a given gene to produce its protein product, that is, due to premature truncation, scrambling of the amino acid code or disrupting gene splicing.
and cellular proliferation 31, 32 . Furthermore, inflammatory signalling mediated by interferon-γ may alter longrange DNA interactions, linking the 9p21 risk alleles to CKDN2A and CDNK2B expression 33 . However, despite scrutiny over the past 10 years, the precise mechanism underlying the 9p21 association remains elusive.
Since 2007, progressively larger sample sizes have been used to interrogate the genetic architecture of CAD, yielding ~60 distinct genetic loci for CAD [34] [35] [36] [37] [38] [39] . The results of this cumulative experience permit several conclusions. First, the vast majority of these variants have a minor allele frequency of >5% in the population, are associated with modest increases in CAD risk (for example, <20% change in risk per allele) and cumulatively explain 30-40% of CAD heritability 39, 40 . By contrast, 15 low-frequency variants (minor allele frequency <5%) identified using a false-discovery rate threshold explained only 2% of CAD heritability 39 . This pattern of results for CAD is similar to that of other complex diseases, including type 2 diabetes mellitus 41 and schizophrenia 42 . Second, most of the variants identified to date are located outside protein-coding regions. Using a genotyping chip designed to capture the vast majority of coding variants in individuals of European ancestry, a recent CVAS identified robust associations for coding variants at only four loci 43 . Rather, a significant enrichment of variants in regulatory regions has highlighted a predominant impact of CAD risk variants on altering gene expression 39, 44 . Third, the genetic loci identified to date have highlighted the biology underlying CAD risk (FIG. 1) . Approximately 20% of the loci are located near genes with known roles in metabolism of LDLs, triglyceriderich lipoproteins (TRLs) or lipoprotein(a) (a modified LDL particle encoded by LPA), reinforcing key roles for these pathways in the development of CAD and providing internal validation of CVAS findings. An additional 5-10% of the loci relate to blood pressure, a known and modifiable causal risk factor for CAD. For example, guanylate cyclase 1, soluble, alpha 3 (GUCY1A3) and nitric oxide synthase 3 (NOS3) are key regulators of vascular tone and platelet aggregation. Common DNA sequence variants at the GUCY1A3 and NOS3 loci have been associated with both blood pressure and CAD 39, 45 . Furthermore, loss-of-function mutations in GUCY1A3 were associated with risk of myocardial infarction in a large family enriched for premature CAD 46 . The equivalent mutations in mice were shown to accelerate thrombus formation in the microcirculation following local trauma 46 . These data highlight a role of nitric oxide signalling in protection against CAD.
Rare variant association studies. A rapid decline in cost has facilitated large-scale genetic sequencing efforts that enable rare variant association studies (RVAS). Such variants are not typically included on genotyping chips (which are designed to capture variation that is common in the population). Furthermore, rare variants do not occur with sufficient frequency to enable association tests of individual variants. Rather, rare variants in a given gene are aggregated into sets enabling a comparison of the aggregate frequency across disease strata 47 . Ongoing and future studies that perform whole-exome or wholegenome sequencing in a large number of individuals will provide additional statistical power for RVAS.
Studies to date have identified at least nine genes for which an aggregation of rare mutations alters the risk of CAD (TABLE 1) . A whole-exome sequencing study comparing ~5,000 cases with early-onset CAD to CADfree controls was used to scan each gene for association with CAD in an unbiased fashion 48 . Unsurprisingly, the strongest signal was noted for damaging mutations in LDLR, which was associated with a fourfold increase in risk of CAD; ~2% of individuals with early-onset CAD harboured a mutation. A second finding was related to inactivating mutations in PCSK9. In contrast to the gain-of-function mutations causative for familial hypercholesterolaemia discussed above, gene sequencing revealed two damaging PCSK9 mutations with an aggregate frequency of 2% of individuals with African ancestry 49 . Carriers of either of these two mutations had substantially lower LDL cholesterol and risk of CAD 50 .
Most recently, a whole-genome sequencing study of Icelandic individuals identified a 12 bp deletion that leads to inactivation of ASGR1 (which encodes asialoglycoprotein receptor) 51 . Heterozygous carriers of this mutation had decreased levels of LDL cholesterol and triglycerides, translating into a decreased risk of CAD.
RVAS have also provided evidence linking genes related to the metabolism of TRLs, in particular those in the lipoprotein lipase (LPL) pathway, with risk of CAD. The enzymatic activity of LPL serves as the ratedetermining step in the clearance of dietary fat from the circulation (FIG. 2) . Individuals harbouring a heterozygous damaging mutation in LPL have increased levels of circulating triglycerides as well as risk of CAD 52 . The activity of LPL is regulated by the protein products of multiple additional genes, several of which have been similarly associated with CAD. Damaging mutations in APOA5, which encodes a protein that enhances LPL activity, are associated with increased CAD risk 48 . By contrast, rare mutations in APOC3 and ANGPTL4, the protein products of which inhibit LPL, are associated with decreased CAD risk 43, [53] [54] [55] .
Biological underpinnings of CAD
From association to mechanism. The numerous genetic loci robustly associated with CAD using the CVAS approach have exposed new mechanisms leading to atherosclerosis. For example, a systematic series of experiments for a novel genetic locus at 1p13, which is associated with increased LDL cholesterol and risk of CAD, identified the causal variant that affected SORT1 expression 34, 56, 57 . Functional studies confirmed a role for sortilin, the protein product of SORT1, in both the secretion of APOB (the major protein component of LDL particles) and LDL catabolism 58, 59 . Similar lines of work hold substantial promise for the identification of novel therapeutic targets, particularly for loci that are not linked to pathways (for example, LDL metabolism) that are currently targeted by available drugs.
Mendelian randomization
A human genetics tool that leverages the random assortment of genetic variants at time of conception to assess causality of observed associations.
ADAMTS7 -a nonlipid cause of CAD identified by human genetics studies.
A 2010 CVAS identified a variant located in an intronic region of a disintegrin and metalloproteinase with thrombospondin motifs 7 (ADAMTS7); this variant was associated with a 19% increase in risk of obstructive CAD (>50% narrowing of a major coronary vessel) 60 . This finding led to substantial interest in elucidating the underlying mechanism, particularly because the variant was not associated with blood lipid levels or other known CAD risk factors. ADAMTS7 belongs to a family of proteins involved in proteolysis (the cleavage of substrate proteins) and remodelling of blood vessel walls. The risk variant at ADAMTS7 seems to be associated with increased gene expression and proteolytic activity, and the ability to promote vascular smooth muscle migration in vitro 61 . Adamts7 knockout mice were noted to have significantly reduced atherosclerosis burden 62 . Furthermore, mice deficient in Adamts7 exhibited decreased cellular proliferation and enhanced endothelial cell repair in response to vascular injury 62, 63 . These results suggest that a pharmaco logical strategy of ADAMTS7 inhibition could prove useful in attenuating the cellular proliferation that plays a key part in CAD progression.
Catalysing drug development for CAD
The development of novel, efficacious and safe therapeutic strategies for CAD remains a major public health need. However, the cost of developing a new drug has continued to increase; a recent analysis estimated direct costs of US$1.4 billion per new compound approved 64 . Much of this cost relates to the vast majority (>95%) of compounds that fail in clinical development, largely owing to inadequate therapeutic efficacy or unanticipated toxicity 65 . Human genetics may provide a key opportunity to improve drug development efforts by confirming the physiological and causal relevance of a given target in humans and anticipating the full range of efficacy and safety consequences of pharmacological modulation 66 (FIG. 3) .
Selection of therapeutic targets by Mendelian random ization.
Human genetics can complement existing preclinical prioritization strategies by providing confidence that a given target is a root cause of CAD in humans. Mendelian randomization studies have emerged as a technique grounded in human genetics to help infer causality between a given biomarker and risk of CAD (FIG. 4) . For example, the large number of common genetic variants linked to lipid levels (>150) provided an opportunity to test the causality of lipid biomarkers using Mendelian randomization 67 . As expected, variants affecting LDL cholesterol levels had robust associ ations with risk of CAD in a concordant fashion 68 . A similar finding was noted for LPA variants affecting the levels of lipo protein(a) 69 . In combination with the sequencing-based analyses of genes related to the LPL pathway discussed above, Mendelian randomization studies have supported a causal relationship between TRLs and CAD, and have reinvigorated interest in Figure 1 | Physiological pathways related to genetic loci associated with coronary artery disease. Genetic loci identified to date are displayed along with the presumed relationship to the causal pathway. Loci are labelled based on the nearest genes because the causal genes and variants have not been definitively identified for most loci; this commonly used form of annotation may prove incorrect in some cases. Adapted from REF. 128 . 71 . A subsequent report from a randomized controlled trial of the drug ezetimibe, which inhibits the protein product of NPC1L1 to decrease cholesterol absorption, confirmed its efficacy in reducing cardiovascular events 72 . By contrast, despite promising observational epidemiology and animal model evidence 73, 74 , lipoprotein-associated phospholipase A 2 (Lp-PLA2; also known as platelet-activating factor acetylhydrolase) inhibitors proved ineffective in multiple trials involving more than 28,000 patients 75, 76 . Genetic studies of both common and rare variants in the gene encoding Lp-PLA2 (PLA2G7) were shown to have no impact on the risk of CAD, raising the possibility that the null clinical trial results might have been foreseen 77, 78 .
Developing therapeutics to mimic protective variants.
The examples of NPC1L1 and PLA2G7 were based on targets with drug development programmes already in place. However, genetic evidence indicating that individuals with inactivating mutations in PCSK9 have decreased levels of circulating LDL cholesterol and reduced risk of CAD fostered intense interest in the development of PCSK9 inhibitors 50 . In 2015, a mere 12 years after the initial discovery of PCSK9 (REF. 15 ), two monoclonal antibodies that inhibit PCSK9 were approved by the US Food and Drug Administration. Each of the drugs led to a ~50% decrease in circulating LDL cholesterol in initial clinical trials and seemed to decrease risk of cardiovascular events; ongoing large clinical trials are seeking to confirm this preliminary signal for efficacy 79, 80 . Similarly, antisense oligonucleotides designed to mimic the protective mutations noted in APOC3 or LPA demonstrated a ~70% reduction in triglyceride levels and 80% reduction in circulating lipoprotein(a) levels, respectively, in early-phase studies 81, 82 . Future studies will seek to demonstrate favourable effect on clinical outcomes.
Phenome-wide association studies. Population-based analyses of variants related to a putative drug target can anticipate the full range of phenotypic consequences that might be expected by pharmacological modulation. For example, a common variant in the gene encoding HMG-coenzyme A reductase (HMGCR), the target of statin therapy, was associated with decreased LDL cholesterol levels but an increased risk of type 2 diabetes 83 . This finding is well aligned with an adverse effect of statins in increasing the risk of diabetes, which was discovered only after decades of clinical trial experience 84 . Furthermore, an ongoing trial is seeking to determine whether anacetrapib, a cholesteryl ester transfer protein . Genetic variants within CETP that are associated with increased HDL cholesterol were recently linked to an increased risk of age-related macular degeneration, a leading cause of blindness [86] [87] [88] . Had this genetic finding been discovered earlier, trial sponsors or regulatory agencies may have requested inclusion of a surveillance programme to determine whether pharmacological inhibition would similarly lead to the toxicity predicted by human genetics.
These examples focus on relationships between genetic variants and candidate phenotypes selected a priori for investigation. However, this concept can be generalized using phenome-wide association studies (PheWAS), which enable the unbiased interrogation of relationships between a given variant and a broad range of human disease states 89 . The utility of this approach is likely to increase in coming years, as large biobanks link genotype information with electronic health records. For example, our group recently leveraged data from >100,000 participants of the UK Biobank to assess the phenotypic consequences of genetically lowered lipoprotein(a) levels on a range of 36 different disease states 90 . Beyond confirming an expected association with decreased risk of CAD and calcific aortic valve stenosis, this PheWAS uncovered relationships with reduced risk of stroke, peripheral vascular disease, congestive heart failure and chronic kidney disease. By contrast, genetic analyses did not replicate toxicity concerns based on observational epidemiology that linked reduced lipoprotein(a) levels to an increased risk of type 2 diabetes or cancer 91, 92 .
Recall by genotype studies. Deep phenotyping of individuals with a genetic variant related to a drug target provides an opportunity to test specific hypotheses in a rigorous fashion. Human genetics has traditionally Dietary fat is absorbed by the small intestine and enters the bloodstream as triglyceride-rich lipoprotein particles known as chylomicrons. These chylomicrons are hydrolysed by LPL to provide free fatty acids (used for energy by muscle tissue or deposited into fat stores) and chylomicron remnant particles. LPL has an additional role in hydrolysing very-low-density lipoprotein (VLDL) particles secreted by the liver to produce intermediate-density lipoprotein (IDL), subsequently degraded into low-density lipoprotein (LDL) particles by hepatic lipase (HL). Both chylomicron remnants and LDL can penetrate the vessel wall and propagate atherosclerotic plaque. LPL activity is the rate-determining step in clearance of dietary fat from the circulation and is highly regulated in the body: apolipoprotein A-V (ApoA-V) and apolipoprotein C-II (ApoC-II) activate LPL, whereas apolipoprotein C-III (ApoC-III), angiopoietin-like 4 (ANGPTL4) and ANGPTL3 each inhibit LPL activity. Rare variant association studies have supported a link between several of the proteins involved in the LPL pathway and coronary artery disease (CAD), including LPL itself, ApoC-III, ApoA-V and ANGPTL4 (TABLE 1) . 
Atherosclerotic plaque
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Synonymous
Rare synonymous
Missense rs3798220
Intronic rs10455872
Splice donor rs41272114
Premature stop/splice site/frameshift Rare loss of fuction . b | A dose-response relationship was noted, such that the impact of a given variant on circulating Lp(a) levels was predictive of the association with CAD. c | To anticipate the full spectrum of phenotypic consequences of Lp(a) reduction, a phenome-wide association study was performed in participants of the UK Biobank. A genetically mediated one standard deviation decrease in levels of Lp(a) was associated with a reduced risk of six distinct diseases 90 . d | An antisense oligonucleotide (ISIS-APO(a)-L Rx ; now known as AKCEA-APO(a)-L Rx ) targeting hepatic production of Lp(a) was associated with a >80% decrease in circulating levels, providing proof of principle that this causal pathway may be targeted in a highly specific fashion. Similar reductions in OxPL-ApoB (oxidized phospholipids on apolipoprotein B) and OxPL-Apo For ANGPTL4, a CAD target validated through human genetics, the identification of a potential toxicity in animal models has raised concern about whether it is an appropriate pharmacological target. A monoclonal antibody-based approach designed to inhibit ANGPTL4, thus mimicking the variants protective against CAD, led to a substantial decrease in TRLs in both mice and non-human primates 55 . However, these compounds also led to abnormal lipid accumulation in abdominal lymph nodes in these model systems, a finding previously observed in both a murine model of ANGPTL4 inhibition and in Angptl4 knockout mice 93, 94 . Phenotyping humans with a lifelong genetic deficiency in ANGPTL4 would provide one way to assess whether this toxicity also has relevance in humans. For example, magnetic resonance imaging can be used to characterize the size and tissue characteristics of abdominal lymph nodes.
A comparison of such features between wild-type controls and those homozygous for an inactivating mutation in ANGPTL4 may prove informative.
Genomic medicine
The substantial progress gained in understanding the genetic underpinnings of CAD in the population has laid the groundwork for the integration of genetic data into routine clinical practice; that is, 'genomic medicine' . If health care providers had widespread access to their patients' genetic data, which may well be the case in coming years, what are the potential implications for the prevention and treatment of CAD? A longstanding debate in the field of complex traits genetics pits the 'common disease-common variant' and 'common disease-rare variant' hypotheses against one another 95 . In the latter, the manifestation of CAD may be reflective of a different monogenic driver in each individual 96 . Rare but large-effect variation could be used to stratify CAD into multiple disease subtypes and treatment directed accordingly. However, although likely to be the case for rare monogenic conditions such as familial hypercholesterolaemia, studies to date have instead suggested that the majority of heritable risk for CAD risk is predicated on common variants. These variants, in combination with environmental factors, lead to a quantitative blend of multiple driving processes in each individual.
Here, we describe the potential utility in identifying individuals with either monogenic or polygenic increased risk for CAD (FIG. 5) . Recent reviews have highlighted an additional potential use of predicting drug efficacy or toxicity based on human genetics, often termed pharmacogenetics 97, 98 .
Lessons learned from familial hypercholesterolaemia.
In principle, familial hypercholesterolaemia, the primary monogenic driver of CAD identified to date, represents a major opportunity to use human genetics to improve cardiovascular health. For example, a national programme initiated in 1994 in the Netherlands involves the genetic testing of individuals with features suggestive of familial hypercholesterolaemia, including family history, physical examination findings and severely elevated LDL cholesterol levels. To date, this programme has identified and provided treatment to thousands of individuals 99 . In practice, the implementation of programmes to systematically identify and treat individuals with familial hypercholesterolaemia at the population scale has proven difficult. Although familial hypercholesterolaemia remains both underdiagnosed and undertreated, efforts at both the national and institutional level to improve recognition are ongoing 100 . Largely owing to cost and logistical concerns, few previous efforts have sought to combine genesequencing data and observed LDL cholesterol levels Nature Reviews | Genetics Figure 4 | Mendelian randomization to identify causal biomarkers for risk of CAD. a | Mendelian randomization analyses require the following parameters: a genetic variant (or group of variants) is robustly associated with the biomarker of interest; the genetic variant is independent of confounders that influence the biomarker or risk of coronary artery disease (CAD); and any impact of the genetic variant on risk of CAD is mediated by the biomarker (as opposed to other pleiotropic genetic effects). Because genetic variants are assorted within the population at the time of conception and largely at random, these analyses are less susceptible to the issues of confounding or reverse causality that commonly limit causal inference from observational epidemiology. An important limitation of such a study is that it requires a robust relationship between the genetic variant and a biomarker: a small effect size mandates a large number of individuals with CAD to achieve adequate power. b | For example, rs6511720 is an intronic variant in the low-density lipoprotein (LDL) receptor (LDLR) gene. Each copy of the T allele is associated with lower LDL cholesterol levels and a decreased risk of CAD 68 . c | Among biomarkers linked with CAD in the population, studies performed to date have supported a causal relationship for some (for example, LDL cholesterol, triglyceride-rich lipoproteins and lipoprotein(a)) and a non-causal relationship for others (for example, high-density lipoprotein (HDL) cholesterol and C-reactive protein).
in the prediction of CAD. We recently found that for any given observed LDL cholesterol, the risk of CAD is substantially higher among those who harbour a familial hypercholesterolaemia mutation compared with those who do not 101 . A direct comparison of serial LDL cholesterol levels between individuals with versus without a familial hypercholesterolaemia mutation confirmed higher cumulative exposure among those with a mutation. This observation supports the hypothesis that an increased lifelong exposure to high LDL cholesterol levels is a key driver of CAD risk and provides evidence for the potential clinical utility of knowing the mutation status of an individual.
The study of familial hypercholesterolaemia has also highlighted concepts of broad relevance to CAD popu lation genetics; that is, penetrance, phenocopy and variant annotation. Incomplete penetrance refers to the finding that not all individuals with a familial hypercholesterolaemia mutation manifest severely elevated cholesterol levels. For example, despite a significant increase in average LDL cholesterol among carriers of a familial hypercholesterolaemia mutation, 27% of these individuals had a normal concentration, reflecting the significant heterogeneity both within and across specific mutations 101 . Second, the majority of cases of severely elevated LDL cholesterol cannot be explained by familial hypercholesterolaemia; a phenocopy of severe hypercholesterolaemia can also occur due to lifestyle or polygenic causes 102, 103 . Among individuals with severe hyper cholesterol aemia (defined as LDL cholesterol >190 mg per dl), only 2% harboured a familial hyper cholesterolaemia mutation 101 . Third, assessing the functional impact of rare missense variants (variant annotation) on the function of a protein is not always straightforward, particularly if a variant has not been seen before. Efforts to centralize annotation based on previous observations and to refine computer prediction algorithms as well as high-throughput functional screening of identified variants are likely to improve efficiency and consistency of this process in coming years.
Human genetics to guide precision medicine therapeutics. For a subset of the genes with validated associations with CAD, pharmacological therapies are available or in development to specifically target a pathway and provide an additional opportunity for risk reduction beyond standard lifestyle and pharmacotherapy recommendations (FIG. 5) . Importantly, although these precision Nature Reviews | Genetics 52 or apolipoprotein A5 (APOA5) 48 increase coronary artery disease (CAD) risk by preventing the clearance of dietary fat and triglyceride-rich lipoproteins from the bloodstream; this risk might be directly attenuated through inhibition of APOC3. Third, those with a genetic predisposition to increased lipoprotein(a) (encoded by LPA), that is, at least two risk variants (at SNP sites rs10455872 or rs3798220) as previously characterized 69 , might be offered an antisense oligonucleotide to decrease circulating levels. Importantly, any such therapies would likely be incorporated in addition to guideline-based cardiovascular risk reduction therapeutics. Furthermore, confirmation that targeted PCSK9 inhibition, APOC3 inhibition, or lipoprotein(a) reduction leads to reduction in CAD events in clinical trials is needed before widespread implementation. By contrast, 20% of individuals tested would be in the top quintile of a polygenic risk score, and this population might be targeted for aggressive lifestyle or pharmacological therapies beyond current treatment guidelines. LDLR, LDL receptor.
medicine therapeutics are likely to be used initially in populations with abnormalities in the pathway, they may well also prove useful for the population at large. For example, the efficacy and safety of statin therapy was initially demonstrated in 1994 in a clinical trial of participants with markedly elevated cholesterol levels and manifest CAD 104 . Numerous trials in ensuing years have demonstrated clinical benefit across a broad range of lower baseline cholesterol and CAD risk, albeit with lower absolute risk reductions 105 . However, only a small proportion of individuals harbour a rare, large-effect mutation in one of the genes discussed above. A more common aetiology of an increased genetic risk is related to a polygenic cause; specifically, the inheritance of a large number of smaller impact, more common risk alleles. For any given individual, a weighted score of risk variants can be calculated to provide a continuous and quantitative measure of genetic risk 106 . This approach was first implemented for CAD in 2008 using DNA sequence variants associated with circulating cholesterol levels and extended in 2009 to nine validated CAD risk variants 34, 107 . Compared with those in the lowest quintile of this polygenic risk score, those in the top quintile were at a more than twofold increased risk of early-onset CAD 34 . This finding has subsequently been confirmed by multiple groups using progressively more variants [108] [109] [110] [111] . As DNA is stable over the course of the lifetime, genetic risk can be ascertained from birth. Polygenic risk scores may therefore be particularly useful in risk prediction among younger patients (for example, children or young adults) in whom the cumulative impact of lifestyle factors is less pronounced. This early knowledge may facilitate an intervention to attenuate this risk. For example, adherence to a healthy lifestyle may be particularly important in these high-risk individuals. A recent ana lysis of individuals at high genetic risk noted a 46% attenuation of risk of incident CAD in those with a favourable versus unfavourable lifestyle 4 . Similarly, among those with a high genetic risk, statin therapy was associated with a nearly 50% reduction in CAD risk 111 . These examples provide key evidence that rather than operating in a deterministic fashion, high genetic risk is indeed modifiable. However, both lifestyle and statin therapy are safe and effective across a broad range of individual-level risk. The approach of targeting therapy according to genetic risk might be of more utility in the allocation of therapies with significant adverse effects (for example, antiplatelet therapies associated with bleeding) or cost (for example, antibody-based therapies).
A key goal of genomic medicine is to disclose genetic risk to individuals and their health care providers to enable behavioural changes or pharmacological therapy to attenuate risk before onset of disease. For example, the MI-GENES study demonstrated that the incorporation of a genetic risk score into shared decision-making sessions with patients and health care providers led to a modest increase in statin utilization and lower LDL cholesterol levels in those with high genetic risk 112 . Ongoing and future studies are needed to determine the optimal approach for genetic risk disclosure and assess whether this approach can improve clinical outcomes.
Future applications of human genetics findings
The study of the genetic architecture of human CAD has led to substantial progress in gene discovery, informing drug development through an improved understanding of human pathophysiology and laying the foundation for genomic medicine. Despite substantial progress, the following key questions regarding the genetics of CAD remain: can human genetics highlight a novel pathway, independent of LDL, TRL and lipoprotein(a) metabolism, that underlies CAD risk? Can genetics facilitate an understanding of the phenotypic consequences of each gene as they relate to CAD? Can the information gained about protective mutations be used to develop a therapy that would effectively cure atherosclerosis in this century?
Functional genomics to highlight novel causal pathways. The CVAS approach has been highly successful in validating a large number of genetic loci linked to CAD. However, for the majority of loci, key questions regarding the mechanisms underlying these associations remain unclear. In particular, the causal DNA variant, the causal gene under regulation, the mechanism by which the variant affects the gene and the mechanism by which the gene influences the risk of CAD. This line of work has proven challenging because the majority of variants lie in non-coding intergenic regions 39 ; thus, even the initial step of identifying the gene of interest (that is, the effector transcript) is often not straightforward.
Successful approaches in functional genomics are likely to require close partnerships between computational and experimental biologists. Deep sequencing of the areas near CVAS loci and Bayesian approaches to prioritize variants can help to identify the causal variant 58, 113 . Insights into the mechanism of gene regu lation can be gained from publicly available databases, including the Encyclopedia of DNA Elements (ENCODE) project, which provides details on histone marks and transcription factor binding sites in the region 114 . The relationship of a given variant with tissue-specific expression of candidate genes (expression quantitative trait loci) can be evaluated using data from the Genotype-Tissue Expression (GTEx) project, thus facilitating integrative network analyses 115 . Epigenetic, metabolomic or proteomic data have become increasingly available and may similarly prove useful. From a functional perspective, more than 100 distinct genes have been shown to influence atherosclerosis in validated mouse models 116 . Collaborative efforts to demonstrate the relevance of such signals using human genetics analyses and, conversely, to use human genetic signals to prioritize candidate genes for animal model validation, represent a key opportunity to move the field forwards. Importantly, viral vectors that facilitate gene overexpression or knockdown in animal models are readily available. Substantial progress in gene editing approaches has dramatically decreased the time needed to engineer mouse models with a variant of interest. Similarly, induced pluripotent stem cells can be isolated from humans with a genotype of interest or engineered into existing cell lines for additional study. This rapidly expanding functional genomics toolkit is likely to accelerate the process of moving from genomic localization to mechanistic discovery in coming years with the ultimate aim of identifying a novel pathway that can be therapeutically targeted 117 .
Genetics at the population scale to understand genomephenome relationships. A robust understanding of the phenotypic consequences of inactivating mutations in a given gene will require very large matrices that link an individual's genetic information with phenotypes (for example, phenotypes from electronic health records); several such resources are currently in use or in development (TABLE 2) . Recent gene sequencing efforts have identified individuals homozygous for rare inactivating mutations (human knockouts) in >1,000 genes; this phenomenon seems to occur with substantially greater frequency in populations with higher rates of consanguinity 118, 119 . Just as the targeted deletion of each gene in the mouse (Knockout Mouse Project) has been an invaluable resource to understand gene function, one might imagine a Human Knockout Project involving a systematic effort to phenotype humans who naturally lack a given gene.
As proof of concept, a recent, preliminary exome sequencing ana lysis identified an individual homozygous for a damaging mutation in APOC3, in whom levels of plasma APOC3 are virtually undetectable 119 . A subsequent call-back study of 27 additional family members confirmed the overall health status of human APOC3 knockouts and a dramatic reduction in TRLs, particularly pronounced after a meal rich in fat. The identification of healthy individuals with an inactivating mutation in both copies of a given gene, effectively 'human knockouts, ' can provide some reassurance that pharmacological inhibition of the gene's product would be tolerated in humans. Additional mechanistic and lipoprotein kinetics studies in these individuals are likely to have direct relevance to APOC3 inhibition as a therapeutic strategy for CAD.
Genome editing as curative therapy.
Despite the demonstrated efficacy of currently available therapies, adherence and adverse effects limit their impact in clinical practice. For example, only 39% of individuals reported adherence to statin therapy in the year following a heart attack, even when the medicine was provided free of charge 120 . As noted above, rare genetic mutations in several genes have been noted to confer lifelong resistance to the development of CAD without detectable toxicity. A gene editing-based therapeutic that introduced such mutations via a one-time injection could extend these protective effects into the population at large. This approach would leverage one of the most significant scientific advances in recent decades, namely use of a CRISPR RNA-guided endonuclease system to cleave sequences of the human genome in a highly specific fashion 121, 122 . A single injection of a viral vector designed to target hepatic PCSK9 using CRISPR-Cas9 led to mutations in ~50% of hepatocytes and a 40% reduction in cholesterol levels in a mouse model 123 . Similar therapeutics could be designed to decrease circulating TRLs, lipoprotein(a) or other causal risk factors for CAD identified in coming years.
Given that this gene editing approach would lead to irreversible change, an abundance of caution is needed before clinical implementation. Ongoing research is seeking to attenuate the immune reaction induced by the viral vectors used to introduce the therapeutic, to increase efficiency and specificity in targeting the desired gene, and to ensure that no other genes are affected (so-called off-target effects). With regard to target selection, careful phenotyping of 'human knockouts' may help ensure that there are no unanticipated side effects of gene inactivation. Gene editing to decrease the expression or function of a gene product is more tractable with current technology. However, for genes in which damaging mutations confer increased risk of CAD (for example, LDLR), future advances may enable upregulation or potentiation of gene activity. Furthermore, alteration of an individual's DNA raises a host of ethical and social questions that will need to be fully explored 124 . However, at present, the majority of individuals in the United States approve of gene editing with the express purpose of improving health or preventing disease 125 .
Conclusions
Here, we reviewed the substantial progress made in understanding the genetic underpinnings of CAD. Moving forwards, the price of genetic sequencing will continue to decrease and an increased emphasis on variant interpretation, functional validation and integration with large-scale phenotyping efforts will become paramount. Over the next 10 years, we are hopeful that human genetics will prove useful in identifying novel root causes of CAD, guiding drug development efforts in anticipating the safety and efficacy profile of a given therapeutic, and providing patients and their health care providers with genetic data that will aid in CAD prevention and treatment.
